S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies?

About this episode

Experts discuss the future of immune effector cell therapies following the National ICE-T Conference.

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymphoma, and other hematologic oncology populations. The experts first discussed ideas from a session dedicated to innovations in CAR T cells and cellular therapies, with Mahmoudjafari emphasizing ongoing work exploring novel constructs such as dual-targeting chimeric antigen receptors (CARs) that may overcome antigen escape. According to Paul, a need remains for determining appropriate biomarkers to identify patients who are most likely to derive long-term benefit from agents like ciltacabtagene autoleucel (Carvykti). Regarding another session related to bispecific antibodies and T-cell–engaging agents, Mahmoudjafari described how many new off-the-shelf therapeutic options are challenging clinicians to rethink care delivery models that can provide both high acuity monitoring and outpatient…

People in this episode

Guests: Zahra Mahmoudjafari, Barry Paul

Topics covered

• immune effector cell therapies
• CAR T-cell therapies
• bispecific antibodies
• hematologic oncology
• treatment paradigms

Keywords

• immune effector cells
• CAR T-cell therapy
• bispecific antibodies
• hematologic cancers
• treatment innovations

Mentioned in this episode

Organizations: CancerNetwork

Products: ciltacabtagene autoleucel

Places: Charlotte, North Carolina

More episodes of Oncology On The Go

• S1 Ep218: Unraveling Key Hematologic Oncology Developments at ASCO 2026 · June 8, 2026 · 24 min
• S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy · June 1, 2026 · 29 min
• S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview · May 28, 2026 · 29 min
• S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation · May 25, 2026 · 11 min
• S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors? · May 18, 2026 · 13 min
• S1 Ep212: Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer · May 4, 2026 · 20 min